Logo image of SABS

SAB BIOTHERAPEUTICS INC (SABS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SABS - US78397T2024 - Common Stock

3.95 USD
-0.09 (-2.23%)
Last: 11/28/2025, 3:01:51 PM
3.96 USD
+0.01 (+0.25%)
After Hours: 11/28/2025, 3:01:51 PM
Fundamental Rating

1

Taking everything into account, SABS scores 1 out of 10 in our fundamental rating. SABS was compared to 533 industry peers in the Biotechnology industry. SABS may be in some trouble as it scores bad on both profitability and health. SABS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SABS has reported negative net income.
SABS had a negative operating cash flow in the past year.
In the past 5 years SABS reported 4 times negative net income.
In multiple years SABS reported negative operating cash flow during the last 5 years.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -122.99%, SABS is doing worse than 80.30% of the companies in the same industry.
SABS's Return On Equity of -308.38% is on the low side compared to the rest of the industry. SABS is outperformed by 71.86% of its industry peers.
Industry RankSector Rank
ROA -122.99%
ROE -308.38%
ROIC N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SABS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for SABS is higher compared to a year ago.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -9.70, we must say that SABS is in the distress zone and has some risk of bankruptcy.
SABS has a Altman-Z score of -9.70. This is in the lower half of the industry: SABS underperforms 72.05% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that SABS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.27, SABS is doing worse than 68.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z -9.7
ROIC/WACCN/A
WACC8.68%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.87 indicates that SABS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.87, SABS is doing worse than 88.74% of the companies in the same industry.
SABS has a Quick Ratio of 0.87. This is a bad value and indicates that SABS is not financially healthy enough and could expect problems in meeting its short term obligations.
SABS's Quick ratio of 0.87 is on the low side compared to the rest of the industry. SABS is outperformed by 88.56% of its industry peers.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.62% over the past year.
The Revenue for SABS has decreased by -40.94% in the past year. This is quite bad
The Revenue for SABS have been decreasing by -72.10% on average. This is quite bad
EPS 1Y (TTM)48.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.61%
Revenue 1Y (TTM)-40.94%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SABS will show a very strong growth in Earnings Per Share. The EPS will grow by 23.44% on average per year.
The Revenue is expected to grow by 130.46% on average over the next years. This is a very strong growth
EPS Next Y38.16%
EPS Next 2Y29.81%
EPS Next 3Y23.44%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y130.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SABS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

SABS's earnings are expected to grow with 23.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.81%
EPS Next 3Y23.44%

More info and screens

0

5. Dividend

5.1 Amount

SABS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (11/28/2025, 3:01:51 PM)

After market: 3.96 +0.01 (+0.25%)

3.95

-0.09 (-2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners18.18%
Inst Owner Change1356.71%
Ins Owners13.76%
Ins Owner Change13.16%
Market Cap41.12M
Revenue(TTM)1.32M
Net Income(TTM)-37.06M
Analysts85
Price Target9.01 (128.1%)
Short Float %7.81%
Short Ratio2.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.22%
Min EPS beat(2)-34.25%
Max EPS beat(2)46.7%
EPS beat(4)1
Avg EPS beat(4)2.11%
Min EPS beat(4)-34.25%
Max EPS beat(4)46.7%
EPS beat(8)4
Avg EPS beat(8)-42.48%
EPS beat(12)7
Avg EPS beat(12)-31.03%
EPS beat(16)10
Avg EPS beat(16)-39.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.87%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 358.5
P/FCF N/A
P/OCF N/A
P/B 3.42
P/tB 3.42
EV/EBITDA N/A
EPS(TTM)-3.03
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-2.97
FCFYN/A
OCF(TTM)-2.96
OCFYN/A
SpS0.01
BVpS1.15
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.99%
ROE -308.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z -9.7
F-Score1
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)828.01%
Cap/Sales(3y)14.46%
Cap/Sales(5y)16.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.61%
EPS Next Y38.16%
EPS Next 2Y29.81%
EPS Next 3Y23.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-40.94%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y130.46%
EBIT growth 1Y8.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-110.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.79%
OCF growth 3YN/A
OCF growth 5YN/A

SAB BIOTHERAPEUTICS INC / SABS FAQ

Can you provide the ChartMill fundamental rating for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to SABS.


Can you provide the valuation status for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to SAB BIOTHERAPEUTICS INC (SABS). This can be considered as Overvalued.


How profitable is SAB BIOTHERAPEUTICS INC (SABS) stock?

SAB BIOTHERAPEUTICS INC (SABS) has a profitability rating of 0 / 10.


How financially healthy is SAB BIOTHERAPEUTICS INC?

The financial health rating of SAB BIOTHERAPEUTICS INC (SABS) is 0 / 10.